How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of endoluminal gastroplication for gastro-oesophageal reflux disease

    Closed for comments This consultation ended on at   Request commenting lead permission

    2In the systematic review and meta-analysis of 1,475 people, the SMD between GORD-HRQL before and after all procedures (follow up range 1.5 to 59 months) was 17.72 (95% CI 17.31 to 18.14; 25 studies, n=1236; P < 0.001; I=94%).

    In the case series of 50 people, the mean GORD-HRQL score (scored 0 to 50 with higher scores indicating increased severity) for patients off PPI decreased from a mean of 46±19 at baseline to 18±13 at 2 years (n=45, p<0.01), 19±14 at 3 years (n=45, p<0.01), 10±7 at 5 years (n=34, p<0.001), 10±7.7 at 7 years (n=24, p<0.001), and 9.5±6.1 at 10-year follow up (n=12, p<0.001; Testoni 2019).

    In the case series of 46 people, the median GORD-HRQL score at baseline in those completing 3-year follow up was 24 (95% CI 9.7 to 30.6) and decreased to 2.5 (95% CI 0.47 to 8.7, p=0.007) after 3 years. The proportion of people who had at least a 50% reduction in symptom score according to GORD-HRQL in ITT analysis was 67% (31/46) at 6 months, 65% (30/46) at 1 year, 64% (25/39) at 2 years and 60% (21/35) at 3 years (Testoni 2022).

    In a case series of 57 patients, median GORD-HRQL score increased from a median of 24 (IQR 15 to 28) to 7 (IQR 2 to 18) after a median 12-month follow up (n=36, p<0.01) and 10 (IQR 6 to 14) after a median 97 month follow up (n=23, p<0.01). Dissatisfaction with GORD symptom management also decreased from a baseline of 100% to 26% after a median follow up of 97 months (Chimikungara 2018).

    Medication usage